| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Why move a 2-pound burrito in a 2-ton car? Meet Serve, the future of sustainable, self-driving delivery.
Appfire launched in 2005 as one of the original partners in the Atlassian software ecosystem. From the start, our focus has always been to help teams customize their tools so they can do better work together. 16 years later and our mission is still the same: support our founders and teams with a powerful platform to build incredible solutions — fueled by innovation and customer feedback.
Lucidum is the asset discovery company that eliminates blind spots across cloud, security and IT operations. Fortune 500 companies rely on the Lucidum platform and its patent-pending machine learning to discover, triangulate and identify all assets – even previously unknown unknowns – delivering visibility essential to truly secure, manage, and transform your enterprise. Backed by GGV Capital and Silicon Valley CISO Investors (SVCI), Lucidum is based in San Jose, California.
From automation to outsourcing with OpenText ApplicationXtender, our solutions enable you to focus on your core business – well do the rest